If you want to build a career in biotech, should you get a PhD after college or join a company directly (as a Research Associate/RA, usually)?
There's no single answer, but I have the conversation often enough that I thought I'd share some pros/cons... (1/n)
First, see this thread about different types of biopharma companies. For reasons I'll get into, I think early stage (probably founder led) biotech is your best bet unless you still want to do PhD later.
(PS if you want to be a professor, it's 💯 PhD) 2/n
PhD will give you more options.
Some companies (incl. @GordianBio) will help you grow from RA to Scientist role (and beyond). But many, esp larger, companies have a glass ceiling if you don't have a PhD. Even if you pick one w/o glass ceiling, you'll be worse off it if fails. 3/n
But a wetlab PhD takes 5-7 years. A good and driven RA could (in right co, with supportive mentor) make Scientist in 3-4. So there's real opportunity cost.
Your salary will also be 2-3x, although at this career stage you should focus on learning > earning if you can. 4/n
(And of course, if you manage to join an extraordinary company the opportunity cost of ~3y is huge. You might end up joining as employee #30 instead of #10, with meaningful differences in equity, learning, and network-building). 5/n
What will you learn? Varies a lot, but PhD should teach 1) experimental design, 2) science communication, 3) the foundations and implicit knowledge of a field, and ideally 4) new skills that very few possess.
RA hopefully 1+2, 3 might need more self-study, and 4 not always. 6/n
OTOH RA can teach you (by exposure) more about how companies work: working within a team, organization coordination, urgency, a higher bar for reproducibility, drug development strategy, and more. These skills are less unique, but more widely applicable. 7/n
(And some of those unique skills turn out to be in little demand, e.g. if you become the leading expert on the reproductive system of roundworms) 8/n
Both can offer smart colleagues, interesting science, and service to humanity.
PhD gives you more independence earlier, RA gives you resources and a sense of urgency earlier. Academia might make you feel like you're in a Kafka story, RA might make you feel like a robot. 9/n
As I said, no clear answer!
If you're very sure about biotech > academia, and you think you've found an exceptional company that will support you, RA could give you the fastest progress. But many RA positions could be a dead end, or at best prep for doing a PhD anyway. 10/n
Should also mention, in either case a LOT of your experience depends on whether your mentor is smart and supportive. Without that you'll be hamstrung and frustrated. Pick the good mentor over other factors 99% of the time. 11/11
This thread is more popular than the one on understanding aging, y'all need to reconsider your priorities 😂
I do know cos hiring RAs (mostly in SF) so any bio grads who decide on that path can email my first name at gordian.bio w your interests and I'll redirect.
Also know people looking for PhD students (in #aging/#longevity at least), but you'll need to apply for the programs first etc. so probably not helpful...
• • •
Missing some Tweet in this thread? You can try to
force a refresh
All these points resonate, for early stage biotech at least. @erlichya touches on this, but I think worth separating "industry" into different clusters that will feel quite different to someone coming from academia (still oversimplified, of course):
Pharma (eg Pfizer) vs biotech:
You wear fewer hats, see less of the company but company as a whole spans wider range of expertise, fewer changes in direction, often higher income but no chance of getting rich. Both have job insecurity: pharma doesn't go die but programs do.
Clinical vs R&D stage biotech:
Clinical may still have R&D but it's no longer the biggest driver of success vs failure. Assay validation/rigor > assay development/invention. Clinical can feel more like pharma, but with more urgency/stakes: one program = life or death of co.
#SciTwitter After a lot of research and asking around, I'm making the lab equipment recommendations 🧵 I wish I'd had 2 months ago. RT/share with a #newPI or startup 🔬⚗️🛒
Note, much of the equipment hasn't arrived yet, will add comments after actual use.
-20 #freezer
Less clear, many viable options. We ended up getting a split of PHC MDF -30 (recommended as quieter) and much cheaper Corepoint Scientific/@VWR, will see which we prefer. Thermo hasn't failed #MBCbiolabs, but $$$ and several people said poor customer support.
As with all experiments, I expect that some of these will disappear and that others will be a central part of science in ten years.
But them happening at all is enough to renew a conversation about how science is funded and conducted.
🦸🏽 While I've been doing most of the tweeting, the Longevity Apprentices @LNuzhna@kush__sharma@edmarferreira & Tara Mei are the real heroes for running the operations.
This has been a great Apprenticeship project, merging action and exposure to research martinborchjensen.com/apprenticeship
🚅 The review + awards process was fairly smooth, thanks in part to @kush__sharma's custom reviewer UI. Several reviewers told us unprompted that it was their best review experience ever; the UI took 2 wks to make, so there's low hanging fruit for other agencies in that area.
Thrilled to announce the Longevity #Impetus Grants, $21M+ towards basic research that could accelerate our understanding and control of human aging.
We welcome proposals from researchers in- and outside the #Aging field. Please share!
Impetus Grants are $10k-500k (w max 10% overhead). Smaller requests favored, to support more projects. No project period and no strings attached. Scientists at non-profits worldwide can apply with ideas that shift perspectives & capabilities in #Aging research, starting Sep 13th.
Inspiration came from @tylercowen & @patrickc's #COVID19 Fast Grants. Their team made funding decisions in 2 weeks, and the grants have already led to both discoveries and better tools for #testing.
If it's feasible to fund science this way, shouldn't we? future.a16z.com/what-we-learne…
Arlan Richardson showing that JAX-housed mice, like humans, have undergone a dramatic improvement in #lifespan this century ... by reducing deaths from pathogens. #MindYourModels
Recommends looking at lifespan data as the best indicator of husbandry quality at different institutions/sources. Mean survival should be at least 27-30 months.
Example: 2003 Igf1r study showing 33% lifespan extension (in het ♀️s), but mean lifespan of controls was only 19mos. Lifespan effect largely disappeared when replicated in cohorts with longer control lifespan.
This was my go-to question for fly lifespan studies as a postdoc.